Positive Study Data for Tibotec HIV Drug
Posted on: Thursday, 17 August 2006, 15:00 CDT
Tibotec Pharmaceuticals' TMC125, a next-generation non-nucleoside reverse transcriptase inhibitor for the treatment of HIV, was shown to be active against a form of the virus which is normally resistant to this kind of drug - according to 48 week study data.
The data, which were presented at the recent Internationals AIDS Conference, were the final 48 week analysis of a phase IIb dose-finding study in HIV-1 infected adult patients with substantial treatment experience, documented evidence of non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance and three or more protease inhibitor mutations.
A total of 199 patients were randomized to TMC125 (400 mg or 800 mg bid) plus background regimen or best available control regimen. 98% of control group patients had discontinued treatment by 48 weeks, compared with 38% of TMC125 patients.
In patients with NNRTI resistance, the viral load reduction in patients receiving TMC125 400mg or 800mg bid in combination with an optimized background regimen was significantly greater than in the active control at 48 weeks.
"These 48 week results in patients with NNRTI-resistance with limited treatment options are encouraging," said Dr Cal Cohen, research director, CRI New England and Harvard Vanguard Medical Associates, Boston.
Source: Datamonitor
Related Articles
- Kouros Azar, M.D. (doctorazar.com), Noted Plastic and Reconstructive Surgeon, Offers Top 10 Tips to Patients to Help Celebrate National Patient Safety Awareness Week
- Patient Safety Awareness Week Tips and Tools
- Pennsylvania Patient Safety Authority Raises Consumer Awareness During National Patient Safety Awareness Week
- NPSF Issues New Universal Patient Compact During Patient Safety Awareness Week
- Valeant Pharmaceuticals Reports Encouraging Phase IIb Results at Treatment Week 12 for Taribavirin
- Zix Corporation Celebrates National Patient Safety Awareness Week With Continued Success in E-Prescribing
- TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
- IntelliDOT(TM) Corp. Applauds Patient Safety Awareness Week, March 4 - 10, 2007
- Preston Hospital Promotes Patient Safety This Week
- Patients With Treatment-Resistant Schizophrenia Get Good News Today at American Psychiatric Association Meeting in Atlanta
 |
 |
User Comments (0)
RSS Feeds